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SUMMARY 24 
Background and Aim: Regular intake of nuts improves lipid profile and thus reduces the 25 
cardiovascular (CV) risk associated with hyperlipidemia. The aim of the study was to investigate the 26 
effect of a dietary intervention with hazelnuts (HZNs, 15-30 g/day, depending on patient weight) on 27 
serum lipid profile, anthropometric parameters and fatty acids (FAs) composition of erythrocyte 28 
phospholipids in children and adolescents with primary hyperlipidemia.  29 
Methods: Eight-week randomized, single blind, controlled, three-arm, parallel-group study. Sixty-six 30 
subjects were enrolled and randomized in 3 groups receiving: 1) hazelnuts with skin (HZN+S); 2) 31 
hazelnuts without skin (HZN-S); 3) dietary advices for hyperlipidemia only (controls). Before and 32 
after intervention, clinical parameters were measured and blood samples were collected for the 33 
evaluation of serum lipid levels and phospholipid FA composition of erythrocytes.  34 
Results: Two-way ANOVA showed a significant effect of time on serum low-density lipoprotein 35 
cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C)/LDL-C ratio and non-HDL-C 36 
(p≤0.001), but not of treatment and time x treatment interaction. In particular, HZN+S and HZN-S 37 
significantly reduced the concentrations of LDL-C and increased HDL-C/LDL-C ratio. HZNs also 38 
had a favorable impact on FAs composition of erythrocyte phospholipids, as demonstrated by time x 39 
treatment interaction, with a significant increase of monounsaturated fatty acids (MUFAs) (p=0.008) 40 
and MUFAs/saturated fatty acids (SFAs) ratio (p=0.002) with respect to the control group.  41 
Conclusions: For the first time, we documented a positive effect of HZN consumption on lipid profile 42 
and FA composition of erythrocyte phospholipids in children with primary hyperlipidemia. Further 43 
studies are encouraged to better define HZN impact on the markers of CV risk in this population. 44 
The trial was registered under ISRCTN.com, ID no. ISRCTN12261900. 45 
 46 
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Abbreviations: BMI, body mass index; CVD, cardiovascular disease; CHILD, cardiovascular health 
integrated lifestyle diet; FA, fatty acid; FCHL, familial combined hyperlipidemia; FH, familial 
hypercholesterolemia; GAE, gallic acid equivalents; HDL-C, high density lipoprotein cholesterol; 
HZN, hazelnuts; HZN+S, hazelnuts with skin; HZN-S, hazelnuts without skin; LDL-C, low-density 
lipoprotein cholesterol; MUFAs, monounsaturated fatty acids; non–HDL-C, non-high density 
lipoprotein cholesterol; PHC, polygenic hypercholesterolemia; PUFAs, polyunsaturated fatty acids; 
RBCs, red blood cells; SFAs, saturated fatty acids; TC, total cholesterol; TE, trolox equivalent; TG, 
triglycerides. 
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1. Introduction 49 
Hyperlipidemia is a well established risk factor of atherosclerosis with detrimental effects on blood 50 
vessels since childhood. Therefore, children with primary hyperlipidemia are at increased risk to 51 
develop cardiovascular disease (CVD) later in life [1]. 52 
Dietary treatments, designed to replace dietary saturated fatty acids (SFAs) and cholesterol with 53 
unsaturated fatty acids, are considered the primary approach in the management of dyslipidemias and 54 
CVD prevention [2]. The American Academy of Pediatrics has suggested specific dietary programs 55 
for children (CHILD1 and CHILD2) to promote growth, avoid adiposity and ameliorate the 56 
lipoprotein profile. These guidelines reinforce the need to limit the intake of total fat and SFAs to 57 
30% and 7-10% of total daily energy, respectively [3].  58 
 The benefits associated with replacing SFAs with monounsaturated fatty acids (MUFAs) and 59 
polyunsaturated fatty acids (PUFAs) on lipid profile and other CV risk factors have been increasingly 60 
demonstrated [4], together with the advantages on CV risk and metabolic profile deriving from 61 
healthy dietary patterns, e.g. the Mediterranean diet, rich in fruit, vegetables, legumes, nuts, whole 62 
grains, dairy products, fish and olive oil [4]. 63 
Moreover, several studies have shown a remarkable cardioprotective effect associated with regular 64 
nut consumption, attributed to the bioactive components contained in the nut kernel and skin, in 65 
particular MUFAs and PUFAs, phytosterols, antioxidant vitamins (e.g. tocopherols), fibers, and 66 
polyphenols [5]. In particular, hazelnuts (HZNs) are characterized by a relatively high content of 67 
polyphenols, playing an important role in improving serum lipid profile through several mechanisms, 68 
including the regulation of cholesterol absorption, the inhibition of triglycerides synthesis and 69 
secretion, and the reduction of low density lipoprotein oxidation [6]. 70 
 A number of intervention studies have assessed health benefits associated with the 71 
consumption of various types of nuts in adults, while only few have been performed in children [7], 72 
and none of them evaluated CVD risk in adult age of children affected by familial hyperlipidemias. 73 
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 Hyperlipidemia and diet composition are two important determinants of cell fatty acid (FA) 74 
composition, which is critical for cell behavior and function [8]. Thus, changes in membrane 75 
properties induced by specific dietary interventions may have important consequences on targeted 76 
cellular functions and, consequently, on CV risk. In this regard, the FA composition of erythrocyte, 77 
which mirrors the tissue FA status [8-10], has been postulated as a useful marker of serum lipoprotein 78 
changes [11]. 79 
 Based on these premises, our study aimed at investigating the effect of a dietary intervention 80 
with roasted Italian HZNs Corylus avellana L., consumed daily for 8 weeks, on anthropometrical and 81 
clinical parameters, serum lipid profile, and FA composition of RBC phospholipids in children and 82 
adolescents with primary hyperlipidemia. Since HZNs can be consumed with skin or peeled, two 83 
intervention arms were considered: the first was represented by patients treated with hazelnut with 84 
skin (HZN+S), the second by patients treated with hazelnuts without skin (HZN-S). A third group of 85 
patients receiving only dietary advices was used as control.  86 
 87 
2. Subjects and methods 88 
2.1. Subjects recruitment 89 
A total of 66 children and adolescents with primary hyperlipidemia (31 females; mean age: 11.6 ± 90 
2.6 years) were selected among 90 followed at the Department of Health Sciences and Pediatrics of 91 
the University of Turin, Turin, Italy. To be enrolled in the study, patients had to be diagnosed with 92 
primary hyperlipidemia, which included familial hypercholesterolemia (FH), familial combined 93 
hyperlipidemia (FCHL) and polygenic hypercholesterolemia (PHC), with serum levels of total 94 
cholesterol (TC) and/or triglycerides (TG) above the age- and sex-specific 90th percentile. Diagnosis 95 
of the various forms of hyperlipidemia was made according to international criteria [12]. In particular, 96 
FH was diagnosed in presence of low-density lipoprotein cholesterol (LDL-C) ≥ 95th percentile, 97 
parental LDL-C ≥ 190 mg/dL, tendon xanthomas and/ or cardiovascular disease (phenotype IIA). 98 
FCHL was diagnosed in children showing TC and/or TG >90th age- and sex-specific percentile, with 99 
6 
 
at least one parent affected by hypercholesterolemia, hypertriglyceridemia, or both (IIA, IV, or IIB 100 
phenotype, respectively), with concomitant individual and familial lipid phenotype variability. 101 
Children with LDL-C levels >90th percentile and a family history of dominant inherited 102 
hypercholesterolemia, but not fulfilling the biochemical international diagnostic criteria of FH or 103 
FCHL were diagnosed with PHC. 104 
Exclusion criteria were food allergies or specific aversion for nut consumption; secondary forms of 105 
hyperlipidemia; obesity, defined as a body mass index (BMI) ≥ 97th percentile, for age and sex (to 106 
exclude a confounding variable); chronic diseases requiring medical treatment; smoking habit; 107 
treatment with lipid-lowering treatment or functional foods in the previous 3 months. Finally, patients 108 
should demonstrate a good dietary compliance, at least in the previous 3 months, assessed by a 109 
questionnaire on food intake and preference. The process of patient selection and allocation to the 110 
different study groups is depicted in Figure 1. 111 
 The study protocol complied with the principles of the Declaration of Helsinki, and was 112 
approved by the Ethics Committee of the Città della Salute e della Scienza, University Hospital of 113 
Turin, Turin, Italy (EC:CS377). The study purpose and protocol were exhaustively explained to all 114 
participants and their parents, who signed an informed consent before study enrollment. The trial was 115 
registered under ISRCTN.com (identifier no. ISRCTN12261900). 116 
 117 
2.2. Hazelnut preparation for the intervention study 118 
Italian HZNs Corylus avellana L., (cultivar ‘Tonda Gentile delle Langhe’, from Piedmont, Italy), 119 
were provided with (HZN+S) or without (HZN-S) skin, in pre-weighed vacuum packed portions. 120 
Roasted nuts were chosen, since they are commonly consumed by the Italian population. All 121 
hazelnuts were roasted for 31 minutes at 135°C. To minimize skin falling, hazelnuts were roasted in 122 
a tunnel oven and collected before the entrance in the cooling tower. Then, only hazelnuts with >80% 123 
of skin were selected and used as “HZN+S” for the intervention trial. Other roasted hazelnuts were 124 
peeled mechanically in the peeling tower and used as “HZN-S”. 125 
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The amount of HZNs per portion was calculated based on the doses advised to adults, adjusted on 126 
children body weight (0.43 g/kg of body weight on average, corresponding to 15-30 g portions).  127 
 128 
2.3. Fat and bioactive composition of hazelnuts 129 
HZNs composition in terms of total fat, sterols and tocopherols content was determined using 130 
standardized methods. The HZN oil was extracted using a cold-pressing method. The recovered oil 131 
was clarified and stored at -18 °C until analyses. Fatty acids composition was obtained through the 132 
analysis of derived methyl esters by gas-chromatography, following the method described by Ficarra 133 
et al. [13]. The fatty acid concentration (expressed as mg of fatty acid/g of oil) was calculated 134 
according to AOAC 963.22 method. The content of minerals was measured by inductively coupled 135 
plasma mass spectroscopy (ICP-MS; Varian 820 ICP-MS) [14]. Polyphenol compounds were 136 
extracted following the method suggested by Ghirardello et al. [15]. The total phenolic content was 137 
assessed by spectrophotometry by means of the modified Folin–Ciocalteu method, and was expressed 138 
as mg of gallic acid equivalents (GAE) per g of sample. Polyphenol composition was determined 139 
using a Thermo-Finnigan Spectra-System HPLC equipped with a Finnigan Surveyor PDA Plus 140 
detector. The separation was achieved at 22 °C on a C18 RP Lichrospher 250 × 4.6 mm, 5-µm column 141 
equipped with a C18 RP Lichrospher 5-µm guard column. The mobile phase was trifluoroacetic 142 
acid/ultrapure water (solvent A) and methanol (solvent B); the flow rate was 0.8 mL min-1, and the 143 
injection volume was 20 µL. The PDA spectra were recorded over a wavelength (λ) range of 200 to 144 
600 nm, and quantification was performed recording the peak area at a maximum λ of each 145 
compound. Identification was achieved by comparing the retention times and spectra of our samples 146 
with those of authentic standards. In addition, the antioxidant capacity (radical scavenging activity) 147 
of the HZN extracts was evaluated according to method of Ghirardello et al. [15]. The results of total 148 
antioxidant activity were expressed as µmoles of Trolox equivalent (TE) per g of sample.  149 
  150 
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2.4. Experimental design 151 
The intervention study was an 8-week randomized, single blind, controlled, three-arm, parallel-group 152 
(Figure 1). Patients were allocated to different treatment groups (with a 1:1:1 ratio, 22 subjects per 153 
group) by a pediatrician who was not involved in the study and did not participate to sample analysis, 154 
according to a randomization list obtained through the investigating center database. Group 1 was 155 
treated with one daily portion of HZN+S; group 2, with one daily portion of HZN-S; group 3 156 
(controls) received only dietary advices. At the beginning of the study, patients assigned to treatment 157 
groups received a HZNs supply sufficient for the complete duration of treatment, portioned into pre-158 
weighed packages, and were asked to consume one portion per day for 8 consecutive weeks. The 159 
control group was advised to follow a nut-free diet for the subsequent 8 weeks. At enrollment, all 160 
children and their parents received nutritional recommendations based on the cardiovascular health 161 
integrated lifestyle diet (CHILD1) guidelines for children with identified hyperlipidemia as supported 162 
by the American Academy of Pediatrics [3]. The essential diet features were: 55% of daily energy 163 
from carbohydrates, 15% from proteins, and 30% from fats (saturated fat 7-10%); dietary cholesterol 164 
<100 mg/1000 kcal and no more than 300 mg/day and 10-25 g/day of soluble fiber. 165 
 All participants were encouraged to maintain the same dietary and lifestyle habits throughout 166 
the study period. To check the compliance to the dietary instructions, the patients and their families 167 
were asked to fill weekly food diaries, before and after enrollment in the study, and were periodically 168 
interviewed for the duration of the study. A nutritionist provided detailed instructions to patients and 169 
their parents on how to record food intake. At the end of the study, dietary records were analyzed to 170 
estimate the average daily energy and nutrient intake. The nutritional evaluation was performed with 171 
Software MètaDieta® (Me.Te.Da S.r.l., San Benedetto del Tronto, Italy) using  Italian Food 172 
Composition databases. 173 
 At baseline and at the end of the study, each patient underwent a medical examination after 174 
an overnight fast, during which blood samples and the physical parameters (i.e. height, weight and 175 
blood pressure) were obtained. Participants in the HZN groups were asked to give back any uneaten 176 
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HZN package at the last visit. Compliance was assessed by weighing the eventual packages returned, 177 
and by analysing weekly food diaries filled at baseline and during the study. 178 
 179 
2.5. Physical evaluation 180 
Height and weight were measured to the nearest 0.1 cm and 0.1 kg respectively (Wunder C-202 and 181 
HR1; Wunder Sa.Bi. srl, Trezzo sull’Adda, Italy). Body mass index (BMI) was calculated as body 182 
weight in kilograms, divided by height squared in meters (kg/m2). The absolute and Z-score values 183 
for weight, height and BMI were reported at baseline. Z-scores were assessed using reference tables 184 
for the Italian pediatric population defined by Cacciari et al. [16]. Blood pressure was measured in 185 
triplicate with a five-minute interval between each measurement using a validated manual mercury 186 
sphygmomanometer (Tycos Classic Hand Aneroid model 5098-02, Welch Allyn, USA) and the mean 187 
of these values was calculated.  188 
 189 
2.6. Biochemical analysis  190 
Fasting venous blood samples were collected into vacutainer tubes containing silicon. Serum levels 191 
of TC, HDL-C and TG were directly determined by an automatic biochemical analyzer (Olympus 192 
AU2700, Japan). The coefficient of variation (CV) was 1.3%, 1.8% and 2% for CT, HDL-C and TG 193 
measurements, respectively. LDL-C concentration was estimated using the Friedewald formula: 194 
LDL-C = TC (mg/dL) − HDL-C (mg/dL) − TG (mg/dL)/5 [17]. Non-high density lipoprotein 195 
cholesterol (non–HDL-C) was calculated subtracting HDL-C from TC. 196 
 197 
2.7. Analysis of FA composition of erythrocyte phospholipids  198 
Fasting venous blood samples of 2.5 ml were drawn into vacutainer tubes containing lithium heparin. 199 
Plasma was separated by tube centrifugation (1400 g x 15 min, 4°C) and stored at -80°C for further 200 
analysis. The buffy layer of white blood cells was removed using a pipette, and erythrocytes were 201 
washed twice in an equal volume of a physiologic solution (0.9% NaCl, w/v). An aliquot (0.5 g) of 202 
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erythrocytes was stored at –80°C for further analysis. FAs extraction from erythrocyte phospholipids 203 
and gas chromatographic analysis were performed in accordance to the method described by 204 
Simonetti et al. [18].  205 
 206 
2.8. Statistical analysis 207 
Sample size was calculated from previous studies in order to detect significant differences in the 208 
serum lipid concentrations and FA composition of erythrocyte phospholipids with a p value of 0.05 209 
and a power of 80% [14, 19]. Based on data from previous studies, eighteen subjects per group were 210 
estimated sufficient to demonstrate a 5% variation of LDL-C concentration with a p value of 0.05 and 211 
a power of 80%. A total of 66 subjects were included considering possible drop-outs. STATISTICA 212 
software (Statsoft Inc., Tulsa, OK, USA) was used for statistical analysis of data. Two-way ANOVA 213 
was applied to compare the effect of treatment and time (before and after treatment) on serum lipid 214 
levels and erythrocyte phospholipids composition. Differences were considered significant for 215 
p≤0.05; post hoc analysis of differences between treatments was assessed by the least significant 216 
difference test with p≤0.05 as level of statistical significance. Finally, regression analysis was used 217 
to define correlations between erythrocyte MUFA levels and serum lipid profile. 218 
 219 
3. Results 220 
3.1. Characterization of hazelnuts 221 
The fat and bioactives composition of 100 g of HZN+S and HZN-S are reported in Table 1. 222 
The major components of HZNs was fat, with a high prevalence of MUFAs, in particular oleic acid. 223 
Furthermore, HZNs contained phytosterols, tocopherols (mainly α-tocopherol), minerals (mainly 224 
potassium, phosphorus, magnesium and calcium). In HZN+S, small amounts of polyphenols (about 225 
13 mg, three-fold higher than in HZN-S) were also detected. Moreover, the HZN+S exhibited a higher 226 
phenolic content (3.9 mg GAE/g), and total antioxidant capacity (18.2 μmol TE/g) than HZN-S (0.8 227 
mg GAE/g and 2.2 μmol TE/g, respectively). 228 
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3.2. Main sample features 229 
Of the 90 hyperlipidemic children and adolescents initially screened for the study, 24 subjects did not 230 
meet the eligibility criteria. The remaining 66 eligible children agreed to participate to the study. Six 231 
participants (4 females) dropped out from the study for personal reasons, not related to the study. 232 
Thus, 60 hyperlipidemic children and adolescents (M/F, 34/26) successfully completed the 8-week 233 
intervention and were included in the data analysis (Figure 1). The study was performed between 234 
January 2015 and October 2015. 235 
Main features of the three groups of patients at baseline and after treatment are reported in 236 
Table 2.  237 
Age ranged from 6.7 to 17.5 years, with a mean age ± SD of 11.6 ± 2.6 years. Mean serum 238 
lipid levels exceeded the 90th age and sex related percentiles, with the exclusion of HDL-C values, 239 
which were in the normal range. Body weight was in the normal range, except for five subjects 240 
presenting with mild overweight, BMI remained unchanged throughout the treatment period. Blood 241 
pressure levels were in the normal range at baseline and during the entire study period. HZN 242 
consumption was appreciated and well tolerated by all patients.  243 
The mean ± SD of z-scores for weight were: 0.27±1.10 in controls, 0.51±1.29 in HZN+S and 244 
0.22±1.04 in HZN-S groups; z-scores for height were: 0.13±1.13 in control, 0.67±1.41 in HZN+S 245 
and 0.29±1.09 in HZN-S groups. Finally, z-scores for BMI were: 0.25±1.11 in control, 0.46±1.36 in 246 
HZN+S and 0.12±1.14 in HZN-S groups.  247 
 Energy and nutrient intake at baseline and during the study period are reported in Table 3. 248 
The intake of HZNs significantly (p<0.05) increased energy, total fat, MUFA and PUFA intake and 249 
reduced carbohydrates intake (Table 3). No differences were observed in the control group. 250 
 251 
3.3. Effect of hazelnuts on serum lipid profile 252 
For each group, the serum lipoprotein concentrations before and after each treatment are reported in 253 
Table 4. 254 
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Following the dietary interventions, a significant effect of time on serum LDL-C (p<0.001), 255 
HDL/LDL ratio (p<0.001) and non-HDL-C (p=0.001), but not of treatment and time x treatment 256 
interaction was detected by the two-way ANOVA. Post-hoc comparisons (LSD test) showed that both 257 
HZN+S and HZN-S treatments significantly reduced the concentrations of LDL-C, and increased 258 
HDL-C/LDL-C ratio, while no effect was observed in the control group (Table 4). HZN-S only 259 
reduced the level of non-HDL-C (Table 4).  260 
 261 
3.4. Effect of hazelnuts on FA composition of erythrocyte phospholipids 262 
The FA composition of phospholipids in erythrocyte at baseline and at the end of treatments are 263 
reported in Table 4. Two-way ANOVA showed a significant effect of time and time x treatment 264 
interaction on total MUFAs (p<0.001 and p=0.008, respectively), and MUFAs/SFAs ratio (p=0.015 265 
and p=0.002 respectively) in erythrocytes, whose levels were significantly higher in patients receiving 266 
HZN after treatment as compared to baseline, and to the control group. An effect of time was observed 267 
for oleic acid (p=0.004) and palmitoleic acid (p=0.015), whose levels significantly increased after 268 
HZN consumption; and of time x treatment interaction for linoleic acid (p=0.043), whose levels 269 
decreased following HZN-S consumption.  270 
In the control group, an increase of SFA (time x treatment interaction, p=0.036) and a decrease of 271 
total PUFA n-6 (time effect, p=0.019) in the erythrocyte phospholipids were detected following 8 272 
weeks of dietary advices. Moreover, a time x treatment interaction was observed for the levels of 273 
margaric acid (p=0.021) that significantly increased, and of eicosenoic acid (p=0.030), that 274 
significantly decreased. A time effect was observed for dihomo-γ-linolenic acid levels (p=0.004), that 275 
significantly decreased compared to baseline. Finally, no significant correlation was found between 276 
MUFA increase in erythrocyte phospholipids and serum lipid response to HZN treatments (data not 277 
shown). 278 
 279 
 280 
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4. Discussion 281 
Nutrition plays a major role in CV prevention. In particular, dietary patterns in childhood impact on 282 
metabolic profile and CV health in adulthood. This concept is relevant when applied to the general 283 
population, and, even more, to children affected by primary hyperlipidemias, whose CV risk is 284 
definitely higher. A healthy diet rich in vegetables and fiber demonstrated to reduce the CV risk later 285 
in life [20]. Fat intake is also critical: the STRIP study, a prospective intervention study involving 286 
children, proved that reducing the intake of saturated fat was effective in reducing LDL-C 287 
concentrations [21]. 288 
To our knowledge, this is the first study evaluating the effects of HZNs intake on lipid profile 289 
and fatty acid composition of RBCs in children and adolescents affected by primary hyperlipidemia. 290 
LDL-C is considered at present the best biomarker of CV risk, and different cut-off levels are 291 
recognized as target levels, depending on age and comorbidities [22].  292 
Although in the HZN groups we observed a significant reduction over time in serum LDL-C 293 
levels to 130 mg/dL, which represents the target for children with primary hyperlipidemia [3], these 294 
changes were not significantly different from those showed in the control group. 295 
Non-HDL-C is considered as a marker of circulating atherogenic lipoproteins, especially 296 
when TG levels exceed 400 mg/dL, a condition limiting the LDL-C significance if calculated by the 297 
Friedewald formula, and correlates with CV risk [22].  298 
In our study, we reported a significant time-effect reduction for non-HDL-C levels in the HZN-299 
S group, possibly suggesting the contribution of HZN in the management of hyperlipidemia, when 300 
added to an appropriate dietary regimen; however, non-HDL-C concentration did not differ 301 
significantly from the other two groups. 302 
The HDL-C/LDL-C ratio, considered a marker of the risk of CV events was also significantly 303 
increased in the present study, although HDL-C levels did not change.  304 
Our results are in line with the observations reported in several dietary intervention studies 305 
performed with HZNs in healthy and/or hyperlipidemic adults. For example, Orem et al. [19], in a 306 
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double-control sandwich model intervention study including 21 hypercholesterolemic adults, found 307 
that a 4-week intervention with HZNs (49-86 g/day raw hazelnuts divided in two portions within the 308 
day) significantly reduced total cholesterol, triacylglycerol and LDL-C, while increasing HDL-C. In 309 
a randomized crossover study, 4-week consumption of ground, sliced or whole HZNs (30 g/day 310 
substituting high saturated fat snacks) improved lipoprotein profile in 48 mildly hypercholesterolemic 311 
adult subjects [23]. In both studies, patients followed isocaloric diets during the whole 312 
experimentation [19;23]. In a well-controlled two-period’s study conducted in 15 young adults with 313 
mildly hypercholesterolemia and hypertrygliceridemia, the supplementation of STEP I diet with 314 
HZNs (40 g/day raw hazelnuts consumed as snack for 8-weeks) increased HDL-C concentrations 315 
while decreasing VLDL-C, triacylglycerol, apolipoprotein B concentrations. In addition, a trend 316 
toward lower levels of total and LDL-C, as well as TC/HDL-C and LDL-C/HDL-C ratios was 317 
documented [24]. 318 
In our study, children maintained their usual dietary program, but increased their energy intake when 319 
allocated to the HZN interventions (by about 100 and 150 kcal after HZN+S and HZN-S, 320 
respectively) and this adds more significance to the detected improvement in lipid profile. 321 
In another study [25], a single 4-week intervention with HZNs (1 g/kg/day; 49-86 g/day of 322 
unpeeled raw hazelnuts) significantly improved plasma lipid and lipoproteins profile in a group of 21 323 
normolipidemic subjects. Similarly, Durak et al. [26] found decreased plasma levels of total and LDL-324 
C and increased HDL-C and TG levels in a group of 30 healthy subjects consuming HZNs for 30 325 
days (1 g/kg/day) in addition to their normal daily diets. Despite the strong limitations of these studies, 326 
including the absence of the randomization, control group, and the type of intervention developed, 327 
these data are in line with our results.  328 
In our study, no significant effect of HZN interventions on TG levels was observed. This 329 
finding is not surprising since TG levels were in the normal range for most of the subjects and in 330 
agreement with Banel & Hu [27] documenting a significant reduction in TG levels only in patients 331 
with serum levels >150 mg/dL. A 12-week intervention with 30- and 60-g/day of HZNs in 332 
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overweight/obese individuals with normal lipid profile produced a reduction of total and LDL-333 
cholesterol, but no effect on HDL-C and TG levels [28]. On the contrary, a recent meta-analysis [29] 334 
demonstrated a positive effect of nuts also on TG levels in subject not affected by CVD. 335 
Based on currently available data, the effect of nut intake on lipid profile and related markers 336 
seems to depend on several nut characteristics, i.e. type, daily dose, preparation, and nutritional 337 
composition of nut cultivars [30-31]. In most of the trials performed in adults, the administered daily 338 
doses of HZN was 0.5 g/kg body weight daily (range 28-30 to 60-70 g per day), being the greatest 339 
effects on LDL–C reduction observed for doses >60 g/day [29]. The characteristics of the subjects 340 
enrolled is also relevant. Indeed, the cardiometabolic health benefits associated with nut consumption 341 
were mainly described in studies conducted in adults reporting a favorable effect on plasma lipid 342 
profile, making the comparison of data difficult in case of pediatric population. In addition to the 343 
present study, only two studies considered the efficacy of nuts in reducing CV risk in children and 344 
adolescents [32-33], but none of them included hyperlipidemic pediatric patients. Scarce data exist 345 
on the impact of factors associated with nut consumption - e.g. time of the day, use of whole single 346 
vs. divided multiple daily portions, and combination with other foods -, on lipid profile and FAs 347 
composition. Moreover, nuts types present important differences in their fat and non-fat constituents 348 
[30-31]. According to our data, similar effects on lipid levels were obtained with unpeeled and peeled 349 
HZNs. Unpeeled HZNs provides a higher amount of polyphenols. The contribution of polyphenols, 350 
as well as of other bioactives (e.g. phytosterols), in the management of dyslipidemia is widely 351 
debated. Growing evidence suggests that polyphenol-rich foods could have a potential lowering effect 352 
of on cholesterol and postprandial triglycerides [6]; however, studies ascertaining the impact of nut 353 
polyphenols in the modulation of lipid profile are scarce. A study performed in atherosclerosis-354 
susceptible mice showed that the consumption of unpeeled walnuts (containing polyphenols), but not 355 
walnut oil (only PUFAs), reduced atherosclerotic plaques and decreased the levels of circulating and 356 
hepatic lipids [34]. Moreover, an extract derived from HZN skin (rich in fiber, phytosterols and 357 
polyphenols) had lipid-lowering blood effects, decreasing the circulating levels of total and LDL-C, 358 
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triglycerides and non-esterified free fatty acids in hamsters fed with a high fat diet for 8 weeks [35]. 359 
In our study, the intake of both HZNs was able to reduce LDL-C and to improve HDL/LDL-C ratio 360 
independently by the polyphenol content.  361 
Another aim of this study was to investigate the effect of HZN intervention in the modulation 362 
of FA composition of erythrocyte phospholipids. The structural properties and function of cell 363 
membranes appear to be modified in dyslipidemic subjects, since the identification of a correlation 364 
between altered FA composition in erythrocyte and adult or pediatric dyslipidemia [9, 36-37]. The 365 
role of diet in the modulation of erythrocyte membrane composition has been evaluated using 366 
different food products [14, 38-39]. Rajaram et al. [40] reported an increase of PUFA, linoleic acid, 367 
and α-linolenic acid in the RBC membranes of normal and mildly hyperlipidemic subjects after 4-368 
week supplementation with walnuts (40 g/day). Similarly, English walnuts intake (30 g/day, 30 days), 369 
a good source of PUFAs, improved erythrocyte PUFA in a group of healthy subjects [38]. In our 370 
study, we found that 8-week HZN intervention increased the levels of MUFAs, oleic acid and 371 
MUFAs/SFAs ratio in HZN treated patients, while no effect was observed in the control group. Since 372 
HZNs provide mainly oleic acid and MUFA, our results support the hypothesis of beneficial effects 373 
associated with HZN-intervention in the modulation of FA composition of erythrocyte phospholipids. 374 
Although no differences in 8 weeks were observed in the control group, we cannot exclude that the 375 
increase in MUFA levels observed following HZNs intake depends on endogenous synthesis more 376 
than diet [41]. Finally, we failed to demonstrate a correlation between the increase in RBC MUFA 377 
levels and serum lipid concentrations after the intake of HZNs possibly because of the small samples 378 
size (data not shown). A significant decrease in the levels of erythrocyte palmitoleic and linoleic acid 379 
was observed only in patients consuming peeled HZN, although these findings remains unexplained. 380 
A reduction of erythrocyte linoleic acid could be postulated as the consequence of ex-novo synthesis 381 
of arachidonic acid, the major n-6 fatty acid contained in erythrocyte membrane. However, the 382 
synthesis rates of arachidonic acid have been reported to be less than 1% [39] and no significant 383 
change in its content was observed following HZN interventions. A significant increase in the levels 384 
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of erythrocyte total SFAs, in particular margaric acid, and a decrease of eicosenoic acid and total 385 
PUFAs n-6 was found in control subjects at the end of the study period. The long chain-PUFA omega-386 
6 dihomo--linolenic acid is the immediate precursor of arachidonic acid and it was found that change 387 
in dairy intake of this fatty acid can increase plasma pentadecanoic and margaric acids in healthy 388 
people [42]. However, based on the analysis of food diaries, no modifications of nutrient intake or 389 
eating behaviors was found. On the contrary, HZN consumption increased the total fat intake, with 390 
specific regard to MUFAs and PUFAs, while decreasing carbohydrate intake, without significantly 391 
affecting total energy intake. Furthermore, we found an overall under-reporting of energy intake as 392 
potential limitation of the study, and a moderate deviation from dietary recommendations. In 393 
particular, protein and fat intake tended to be higher than suggested. BMI did not significantly change 394 
over the intervention, in agreement with results reported in a recent meta-analysis of controlled trials 395 
[29]. 396 
A low omega-3 index (<4%), defined as the sum of eicosapentaenoic and docosahexaenoic 397 
acids contained within phospholipids of erythrocyte membranes, is considered a marker of CV risk 398 
[43] and it was found [44] in obese children and in the same group of hyperlipidemic children and 399 
adolescents characterized in our previous study [37]. As expected for the typical HZN lipid 400 
composition, HZN treatment did not significantly improve this parameter. 401 
Despite the relatively small sample of pediatric patients enrolled, the promising results 402 
obtained in the present study are pivotal for future dietary interventions on this target population. 403 
In conclusion, this is the first intervention trial assessing the effects of HZN-enriched diet in children 404 
affected by primary hyperlipidemia. Based on our results, HZN interventions increased MUFA and 405 
reduce MUFA/SFA ratio in erythrocyte phospholipids in respect to control treatment. Moreover, 406 
regular HZN intake seems to reduce serum LDL-C levels over time, even if the levels did not differ 407 
significantly from those observed in the control group. Although preliminary, these data provide new 408 
information on the potential impact of HZN consumption, in combination with specific dietary 409 
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guidelines, in the management of hyperlipidemia since childhood. Future studies are needed to better 410 
define HZN impact on these and other markers of CV risk in the same target population. 411 
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Table 1. Characterization of fat and bioactives composition of hazelnut Corylus avellana L. ‘Tonda Gentile delle Langhe’. 556 
 557 
 HZN+S  HZN-S  
Total fats (%)  48.5 52.9 
Fatty acids (%)   
14:0 (myristic acid) 0.03 0.03 
16:0 (palmitic acid)  5.85 6.02 
16:1 cis-9 (palmitoleic acid)  0.23 0.22 
17:0 (margaric acid)  0.05 0.05 
18:0 (stearic acid)  2.46 2.7 
18:1 trans-9 (elaidic acid)  0.02 0.02 
18:1 cis-9 (oleic acid)  83.94 84.52 
18:2 cis-9, cis-12 (linoleic acid)  6.93 5.97 
20:0 (arachidic acid)  0.13 0.13 
20:1 cis-13 (paullinic acid)  0.13 0.12 
18:3 cis-6, cis-9, cis-12 (γ-linolenic acid) 0.1 0.1 
22:0 (behenic acid)  0.02 0.02 
20:4 cis-5, cis-8, cis-11, cis-14 (arachidonic acid)  0.03 0.03 
Sterols (%)   
Cholesterol  0.1 0.1 
Campesterol  4.2 4.1 
Campestenol  0.2 0.2 
Stigmasterol  0.9 0.9 
Delta-7-campesterol  - 0.1 
Delta-5.23-stigmastadienol  0.4 0.2 
Chlerosterol  0.9 1 
β-Sitosterol  81.4 82 
Sitostanol  2.4 2 
Delta-5-avenasterol  4.9 5.5 
Delta-5.24-stigmastadienol  0.7 0.9 
Delta-7-stigmastenol  2.7 1.9 
Delta-7-avenasterol  1.2 1.1 
Total sterols (mg/100g) 147.4 147.4 
Tocopherols and tocotrienols (mg/100 g)   
α-Tocopherol  22.9 32.3 
β-Tocopherol 0.5 0.6 
γ-Tocopherol  1.1 0.6 
Total tocopherols  24.4 33.5 
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Minerals (mg/100 g)   
Magnesium 141.0 142.0 
Potassium 597.0 595.0 
Calcium 119.0 118.0 
Manganese 1.75 1.6 
Iron 3.4 3.1 
Zinc 1.8 1.8 
Phosphorus 418.0 424.0 
Copper 1.4 1.5 
Polyphenols (mg/100 g)   
Gallic acid 2.9 1.9 
Procyanidin B1 1.7 1.2 
Epigallocatechin 1.3 - 
Procyanidin B2 2.8 - 
Epigallocatechin gallate 1.7 - 
Gallocatechin gallate 1.9 1.3 
Epicatechin gallate 0.4 - 
Total phenolic content (mg GAE/g) 3.9 0.8 
Total antioxidant capacity (μmol TE/g) 18.2 2.2 
HZN+S: hazelnut with skin; HZN-S: hazelnuts without skin. The phenolic content (Folin–Ciocalteu method) was expressed as mg of gallic acid 558 
equivalents (GAE) per g of sample. The antioxidant capacity (radical scavenging activity) is expressed as µmoles of trolox equivalent (TE) per g of 559 
sample. 560 
561 
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Table 2. Main sample features at baseline and after 8 weeks of intervention.  562 
 563 
Variables 
Control (n=18) HZN+S (n=22) HZN-S (n=20) 
T 
Effect 
t 
Effect 
T x t 
Interaction 
Baseline Week 8 Baseline Week 8 Baseline Week 8 p p p 
Age (years) 12.2 ± 2.3 12.4 ± 2.3 10.8 ± 2.5 11.0 ± 2.5 11.8 ± 2.8 12.0 ± 2.8 0.196 <0.001 0.003 
Sex (male/female) 13/5 12/10 9/11    
Weight (kg) 49.5 ± 16.5  50.0 ± 16.6 44.4 ± 15.3 45.0 ± 15.3 47.8 ± 16.6 48.4 ± 16.5 0.595 0.001 0.952 
Height (cm) 151.8 ± 15.6 152.9 ± 16.0 145.8 ± 14.6 146.6 ± 14.5 151.2 ± 17.2 151.9 ± 17.0 0.402 < 0.001 0.397 
BMI (kg/m2) 20.9 ± 3.9 20.8 ± 4.0 20.4 ± 4.0 20.3 ± 4.0 20.3 ± 3.7 20.3 ± 3.5 0.880 0.847 0.915 
SBP (mmHg) 106.8 ± 9.8 109.0 ± 7.5 103 ± 9.9 105.2 ± 9.3 102.8 ± 10.3 102.5 ± 10.3 0.155 0.252 0.610 
DBP (mmHg) 68.0 ± 5.1 67.1 ± 6.9 65.6 ± 6.6 66.5 ± 7.0 65.1 ± 9.3 66.3 ± 7.4 0.600 0.703 0.687 
 564 
BMI: body mass index; HZN+S: group treated with hazelnut with skin; HZN-S: group treated with hazelnuts without skin; T, treatment effect; t, time 565 
effect; T x t, treatment x time interaction. Values are expressed as mean ± SD.  566 
567 
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Table 3. Daily energy and nutrient intakes assessed by patient food diaries, before and after 8 weeks of treatment. 568 
 569 
Variables 
Control (n=18)   HZN+S (n=22)  HZN-S (n=20) 
T 
Effect 
t 
Effect 
T x t 
Interaction 
Baseline Week 8  Baseline Week 8  Baseline Week 8 p p p 
Energy (kcal) 1126.5 ± 281 1163.5 ± 14  1093.2 ± 194.7 1199.3 ± 180.1*  1241.0 ± 210.2 1358.7 ± 211.0* 0.026 0.002 0.432 
Protein (% of energy) 17.0 ± 2.6 16.4 ± 2.9  17.5 ± 2.9 16.9 ± 2.6  16.5 ± 2.4 16.3 ± 2.3 0.612 0.095 0.822 
Carbohydrate (% of energy) 50.7 ± 4.3 50.3 ± 3.9  51.2 ± 3.8 46.9 ± 3.6*  52.6 ± 3.9 48.6 ± 4.2* 0.413 <0.001 0.008 
Total fat (% of energy) 32.5 ± 3.0 33.3 ± 3.1  31.2 ± 2.9 36.2 ± 1.9*  30.9 ± 2.5 35.2 ± 2.8* 0.609 <0.001 <0.001 
SFA (% of energy) 10.1 ± 2.6 10.0 ± 2.2  9.4 ± 1.4 9.6 ± 1.6  8.9 ± 1.9 8.6 ± 1.9 0.102 0.618 0.722 
MUFA (% of energy) 14.7 ± 1.9 15.5 ± 3.0  13.1 ± 3.3 17.8 ± 6.5*  17.9 ± 2.5 19.0 ± 2.1* 0.466 <0.001 0.037 
PUFA (% of energy) 3.5 ± 0.9 3.3 ± 0.5  4.1 ± 2.3 7.6 ± 3.3*  3.3 ± 1.4 6.8 ± 3.5* 0.002 <0.001 0.003 
ω-3 (% of energy) 0.6 ± 0.1 0.6 ± 0.1  0.7 ± 0.5 1.3 ± 0.6*  0.5 ± 0.3 1.0 ± 0.7* 0.008 <0.001 0.044 
ω-6 (% of energy) 2.2 ± 0.8 2.1 ± 0.4  2.8 ± 2.0 6.0 ± 2.8*  2.1 ± 1.2 5.4 ± 2.9* <0.001 <0.001 0.002 
Fibers (g) 9.0± 2.6 9.9 ± 2.5  10.1 ± 2.1 10.5 ± 2.9  11.9 ± 4.8 14.1± 5.3 0.011 0.143 0.221 
Cholesterol (mg) 137.5 ± 35.9 138.8 ± 59.1  129.9 ± 39.9 123.6 ± 39.3  133.6 ± 44.8 128.8 ± 45.2 0.739 0.594 0.881 
HZN+S: group treated with hazelnut with skin; HZN-S: group treated with hazelnuts without skin; MUFAs: monounsaturated fatty acids; PUFAs: 570 
polyunsaturated fatty acids; SFAs: saturated fatty acids; T, treatment effect; t, time effect; T x t, treatment x time interaction. Values are expressed as 571 
mean ± SD. * Significantly different as compared to baseline (p≤ 0.05). 572 
573 
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Table 4. Serum lipid profile and fatty acid composition of erythrocyte phospholipids at baseline and after 8-weeks of each treatment. 574 
 575 
Lipid profile 
Control (n=18)  HZN+S (n=22)  HZN-S (n=20) 
T 
Effect 
t 
Effect 
T x t 
Interaction 
Baseline Week 8   Baseline Week 8   Baseline Week 8 p p p 
Serum lipids (mg/dl)            
TC  210.3 ± 50.0 204.1 ± 44.9  215.8 ± 42.0 210.5 ± 41.8 221.6 ± 55.6 212.3 ± 52.3 0.815 0.013 0.820 
TG  76.5 (35-185) 77.5 (38-165)  67.0 (32 - 194) 58.5 (37 - 159) 61.5 (46-300) 70 (41-264) 0.400 0.190 0.669 
HDL-C  55.4 ± 14.9 55.5 ± 12.2  62.0 ± 13.6 63.2 ± 14.3 
 61.0 ± 16.2 62.4 ± 16.9 0.250 0.393 0.871 
LDL-C  136.7 ± 45.2 131.9 ± 45.4  141.9 ± 46.8 132.7 ± 44.1* 
 141.4 ± 57.3 132.6 ± 55.3* 0.978 < 0.001 0.604 
HDL/LDL ratio 0.45 ± 0.24 0.49 ± 0.31  0.49 ± 0.19 0.53 ± 0.21* 
 0.50 ± 0.24 0.55 ± 0.27* 0.763 < 0.001 0.853 
HDL/TG ratio 0.76 ± 0.41 0.82 ± 0.41  1.03 ± 0.50 1.06 ± 0.52 
 0.9 ± 0.5 0.9 ± 0.5 0.210 0.256 0.967 
Non-HDL-C 154.9 ± 47.5 148.6 ± 46.9 153.8 ± 46.5 147.3 ± 46.7 
 162.4 ± 59.4 151.7 ± 56.1* 0.911 0.001 0.675 
Phospolipid FA composition of erythrocytes (%)            
Total SFAs 48.52 ± 2.79 49.85 ± 5.06*  49.23 ± 2.23 48.81 ± 3.01 49.73 ± 1.61 48.97 ± 2.05 0.877 0.880 0.036 
Total MUFAs 18.57 ± 1.07 18.49 ± 1.52  18.3 ± 0.75 19.10 ± 0.94* 
 18.41 ± 0.95 19.23 ± 1.01* 0.576 < 0.001 0.008 
Total PUFAs 32.91 ± 2.75 31.67 ± 6.10  32.47 ± 2.12 32.09 ± 3.03 
 31.85 ± 1.97 31.80 ± 2.10 0.743 0.080 0.329 
MUFAs/SFAs ratio 0.38 ± 0.04 0.37 ± 0.03  0.37 ± 0.03 0.39 ± 0.04* 
 0.37 ± 0.02 0.39 ± 0.03* 0.861 0.015 0.002 
PUFAs/SFAs ratio 0.68 ± 0.10 0.64 ± 0.15  0.66 ± 0.07 0.66 ± 0.12 
 0.64 ± 0.06 0.65 ± 0.07 0.763 0.321 0.144 
Total PUFAs n-3 5.16 ± 1.28 4.79 ± 1.53  4.73 ± 0.77 4.60 ± 0.78 
 4.82 ± 0.91 4.93 ± 0.93 0.556 0.138 0.097 
Total PUFAs n-6 25.90 ± 1.26 25.19 ± 4.46  26.08 ± 1.88 25.8 ± 2.19 
 25.58 ± 1.38 25.30 ± 1.48 0.545 0.019 0.546 
PUFAs n-3/n-6 0.20 ± 0.05 0.19 ± 0.06  0.18 ± 0.04 0.18 ± 0.04 
 0.19 ± 0.04 0.20 ± 0.04 0.557 0.572 0.077 
Total LC-PUFAs n-3 5.08 ± 1.28 4.7 ± 1.52  4.64 ± 0.78 4.52 ± 0.77 
 4.72 ± 0.90 4.85 ± 0.93 0.568 0.161 0.079 
Total LC-PUFAs n-6 14.89 ± 1.47 14.23 ± 3.58  15.02 ± 1.64 14.73 ± 1.92 
 14.69 ± 1.32 14.95 ± 1.62 0.791 0.248 0.183 
LC-PUFAs n-3/n-6 0.34 ± 0.08 0.33 ± 0.08  0.32 ± 0.08 0.31 ± 0.07 
 0.32 ± 0.07 0.33 ± 0.07 0.658 0.509 0.507 
Omega-3 index 3.94 ± 1.09 3.66 ± 1.24  3.57 ± 0.74 3.49 ± 0.70 
 3.63 ± 0.79 3.76 ± 0.83 0.602 0.253 0.070 
Saturated fatty acids (%)     
   
    
14:0 (myristic acid) 0.38 ± 0.07 0.40 ± 0.24  0.39 ± 0.09 0.39 ± 0.08 
 0.42 ± 0.08 0.39 ± 0.08 0.733 0.526 0.272 
15:0 (pentadecanoic acid) 0.16 ± 0.03 0.16 ± 0.04  0.16 ± 0.03 0.16 ± 0.03 
 0.16 ± 0.03 0.16 ± 0.03 0.819 0.853 0.555 
16:0 (palmitic acid) 23.83 ± 1.07 24.40 ± 2.80  24.01 ± 1.43 24.08 ± 1.72 
 24.17 ± 1.50 23.63 ± 1.28 0.846 0.888 0.148 
17:0 (margaric acid) 0.46 ± 0.13 0.51 ± 0.34*  0.38 ± 0.19 0.41 ± 0.16 
 0.47 ± 0.14 0.43 ± 0.12 0.174 0.370 0.021 
18:0 (stearic acid) 15.02 ± 1.53 15.17 ± 1.63  15.56 ± 1.02 15.21 ± 1.66 
 15.95 ± 1.36 15.77 ± 1.28 0.211 0.440 0.482 
20:0 (arachidic acid) 0.63 ± 0.25 0.60 ± 0.09  0.56 ± 0.05 0.57 ± 0.07 
 0.55 ± 0.07 0.55 ± 0.07 0.107 0.706 0.863 
22:0 (behenic acid) 2.07 ± 0.36 2.19 ± 0.26  2.06 ± 0.22 1.99 ± 0.35 
 2.03 ± 0.25 2.04 ± 0.26 0.445 0.532 0.080 
23:0 (tricosanoic acid) 0.30 ± 0.05 0.32 ± 0.07  0.33 ± 0.06 0.32 ± 0.07 
 0.31 ± 0.05 0.33 ± 0.12 0.751 0.504 0.581 
24:0 (lignoceric acid) 5.68 ± 0.81 6.09 ± 0.85  5.78 ± 0.81 5.69 ± 1.11 
 5.65 ± 0.85 5.68 ± 0.84 0.712 0.239 0.137 
Monounsaturated fatty acids (%)    
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16:1n-9 (hypogeic acid) 0.11 ± 0.02 0.11 ± 0.03  0.10 ± 0.02 0.11 ± 0.04 
 0.11 ± 0.03 0.10 ± 0.02 0.850 0.831 0.084 
16:1n-7 (palmitoleic acid) 0.22 ± 0.06 0.22 ± 0.16  0.24 ± 0.09 0.23 ± 0.08 
 0.26 ± 0.07 0.24 ± 0.07* 0.479 0.015 0.184 
18:1n-9 (oleic acid) 10.86 ± 1.09 10.88 ± 1.39  10.89 ± 0.79 11.31 ± 1.06* 
 10.93 ± 0.85 11.48 ± 0.95* 0.536 0.004 0.166 
18:1n-7 (vaccenic acid) 1.08 ± 0.07 1.05 ± 0.08  1.06 ± 0.11 1.08 ± 0.13 
 1.09 ± 0.11 1.08 ± 0.07 0.744 0.685 0.196 
20:1n-9 (eicosenoic acid) 0.23 ± 0.13 0.19 ± 0.07*  0.19 ± 0.02 0.20 ± 0.03 
 0.19 ± 0.02 0.20 ± 0.03 0.426 0.459 0.030 
24:1n-9 (nervonic acid) 6.06 ± 1.21 6.05 ± 0.88  5.82 ± 0.80 6.16 ± 1.10 
 5.83 ± 0.79 6.12 ± 0.78 0.958 0.082 0.426 
Polyunsaturated ω-6 fatty acids (%)    
    
    
18:2n-6 (linoleic acid) 10.68 ± 1.12 10.69 ± 1.52  10.78 ± 0.99 10.79 ± 1.16 
 10.59 ± 1.06 10.06 ± 0.97* 0.312 0.088 0.043 
18:3n-6 (γ-linolenic acid) 0.06 ± 0.02 0.06 ± 0.03  0.06 ± 0.02 0.06 ± 0.02 
 0.06 ± 0.02 0.06 ± 0.03 0.688 0.530 0.943 
20:2n-6 (eicosadienoic acid) 0.27 ± 0.10 0.23 ± 0.04  0.22 ± 0.03 0.23 ± 0.03 
 0.24 ± 0.03 0.23 ± 0.04 0.220 0.090 0.190 
20:3n-6 (dihomo-γ-linolenic acid) 1.91 ± 0.43 1.82 ± 0.48  1.87 ± 0.37 1.81 ± 0.39 
 1.94 ± 0.38 1.88 ± 0.41 0.842 0.004 0.813 
20:4n-6 (arachidonic acid) 11.11 ± 1.01 10.62 ± 2.69  11.18 ± 1.41 10.93 ± 1.31 
 10.89 ± 0.98 11.09 ± 1.15 0.865 0.183 0.130 
22:4n-6 (adrenic acid) 1.88 ± 0.57 1.78 ± 0.61  1.97 ± 0.49 2.00 ± 0.77 
 1.86 ± 0.42 1.98 ± 0.60 0.673 0.788 0.447 
Polyunsaturated ω-3 fatty acids (%)    
    
    
18:3n-3 (α-linolenic acid) 0.08 ± 0.03 0.08 ± 0.04  0.08 ± 0.02 0.08 ± 0.03 
 0.10 ± 0.04 0.09 ± 0.03 0.142 0.158 0.461 
20:5n-3 (eicosapentaenoic acid) 0.35 ± 0.13 0.33 ± 0.16  0.36 ± 0.22 0.33 ± 0.14 
 0.34 ± 0.17 0.34 ± 0.17 1.000 0.133 0.666 
22:5n-3 (docosapentaenoic acid) 1.14 ± 0.27 1.05 ± 0.35  1.07 ± 0.14 1.03 ± 0.19 
 1.09 ± 0.16 1.09 ± 0.15 0.684 0.068 0.291 
22:6n-3 (docosahexaenoic acid) 3.58 ± 0.99 3.33 ± 1.17   3.22 ± 0.60 3.17 ± 0.59   3.29 ± 0.68 3.42 ± 0.71 0.506 0.363 0.064 
FA. fatty acid; HDL-C: high-density lipoprotein cholesterol; HZN+S: group treated with hazelnut with skin; HZN-S: group treated with hazelnuts 576 
without skin; LC-PUFAs: long chain polyunsaturated fatty acids (C ≥20. double bonds ≥3); LDL-C: low-density lipoprotein cholesterol; MUFAs: 577 
monounsaturated fatty acids; omega-3 index: sum of eicosapentaenoic acid + docosahexaenoic acid; PUFAs: polyunsaturated fatty acids; SFAs: 578 
saturated fatty acids; T. treatment effect; t. time effect; T x t. treatment x time interaction; TC: total cholesterol; TG: triglycerides.  579 
Values are expressed as mean ± SD or median (min-max). * Significantly different as compared to baseline (p< 0.05).  580 
581 
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Figure 1. Study flow-chart showing the process of patient selection and enrollment. allocation to the three study groups. and rate of patients completing 582 
the study. HZN+S: group treated with hazelnuts with skin; HZN-S: group treated with hazelnuts without skin; control: no treatment group. 583 
 584 
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